We were able to determine that 36.1% (51/141) of alterations in BRCA1, BRCA2, ATM, CDH1, PALB2, BARD1, BRIP1, CHEK2, and RAD51C were identified on tumor sequencing tests in patients with breast, prostate, ovarian, and pancreas cancer were also identified on germline tests indicating that tumor-only CGP does have some utility in discovering clinically relevant inherited alterations in addition to somatic drivers. This evidence concerns the gene BRCA2 and neoplasm.